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NMR study of complexes between low molecular mass inhibitors
and the West Nile virus NS2B-NS3 protease
Abstract
The two-component NS2B-NS3 protease of West Nile virus is essential for its replication and presents
an attractive target for drug development. Here, we describe protocols for the high-yield expression of
stable isotope-labelled samples in vivo and in vitro. We also describe the use of NMR spectroscopy to
determine the binding mode of new low molecular mass inhibitors of the West Nile virus NS2B-NS3
protease which were discovered using high-throughput in vitro screening. Binding to the
substrate-binding sites S1 and S3 is confirmed by intermolecular NOEs and comparison with the
binding mode of a previously identified low molecular mass inhibitor. Our results show that all these
inhibitors act by occupying the substrate-binding site of the protease rather than by an allosteric
mechanism. In addition, the NS2B polypeptide chain was found to be positioned near the
substrate-binding site, as observed previously in crystal structures of the protease in complex with
peptide inhibitors or bovine pancreatic trypsin inhibitor. This indicates that the new low molecular mass
compounds, although inhibiting the protease, also promote the proteolytically active conformation of
NS2B, which is very different from the crystal structure of the protein without inhibitor.
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Summary 
 
The two-component NS2B-NS3 protease of West Nile virus (WNV) is essential for its 
replication and presents an attractive target for drug development. Here we describe 
protocols for high-yield expression of stable isotope-labelled samples in vivo and in vitro 
and the use of nuclear magnetic resonance (NMR) spectroscopy to determine the binding 
mode of new low-molecular weight inhibitors of the WNV NS2B-NS3 protease which 
were discovered by high-throughput in vitro screening. Binding to the substrate binding 
sites S1 and S3 is confirmed by intermolecular NOEs and comparison with the binding 
mode of a previously identified low molecular weight inhibitor. Our results show that all 
these inhibitors act by binding to the substrate binding site of the protease rather than by 
an allosteric mechanism. In addition, the NS2B polypeptide chain was found to be 
positioned near the substrate binding site, as observed previously in crystal structures of 
the protease in complex with peptide inhibitors or bovine pancreatic trypsin inhibitor. 
This indicates that the new low-molecular weight compounds, while inhibiting the 
protease, also promote the proteolytically active conformation of NS2B which is very 
different from the crystal structure of the protein without inhibitor. 
 
 
 
 
 
 
 
 
 
Keywords: West Nile virus, NS2B-NS3 protease, inhibitors, NMR spectroscopy, drug 
development 
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Introduction 
 
West Nile virus (WNV) encephalitis is a mosquito-borne disease that mainly infects 
birds but also animals and humans. It occurs in Africa, Europe and Asia and, since 1999, 
has also been spreading in North America, causing several thousand cases per year, with 
a fatality rate of about 5% reported by the US Department of Health [1].  
West Nile virus is a member of the flavivirus genus along with yellow fever virus, 
dengue virus (DENV), and Japanese encephalitis virus all of which cause human diseases. 
There is neither a vaccine nor specific antiviral therapy currently in existence for WNV 
encephalitis in humans. During infection, the flavivirus RNA genome is translated into a 
polyprotein, which is cleaved into several components. Nonstructural protein 3 (NS3) is 
responsible for proteolysis of the polyprotein through its serine protease N-terminal 
domain (NS3pro), in conjunction with a segment of about 40 residues from the NS2B 
protein acting as a co-factor. NS3 is essential for viral replication and therefore presents 
an attractive drug target. The C-terminal two-thirds of NS3, which contain a nucleotide 
triphosphatase, an RNA triphosphatase and a helicase, have been shown to have little 
influence on the protease activity [2], although the 3D structure of the full-length DENV-
4 NS3 protease-helicase suggests that the protease domain assists the binding of 
nucleotides to the helicase and could also participate in RNA unwinding [3]. 
Crystal structures have been reported of WNV NS2B-NS3pro in the absence of 
inhibitor [4] and in the presence of peptide inhibitors [5,6] or bovine pancreatic trypsin 
inhibitor (BPTI) [4]. The structure in the absence of inhibitor shows the β-hairpin of 
NS2B positioned far (almost 40 Å) from the active site. As the C-terminal residues of 
NS2B are not only essential for full catalytic activity of WNV NS2B-NS3pro [7,8] but 
are also found near the active site in the structures with peptide inhibitors and BPTI, the 
proteolytically most active conformation must be represented by the structures observed 
with inhibitors rather than the one without inhibitor. The function of the protease is 
preserved in a 28 kDa construct, where NS2B and NS3pro are fused via a Gly4-Ser-Gly4 
linker (Figure 2) [2,9].  
A number of low-molecular weight non-peptidic inhibitors were generated in hit-to-
lead activities following a high-throughput screen (HTS) directed against dengue virus 
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NS2B-NS3 protease [10]. Due to the high sequence homology between DENV and WNV, 
many of the compounds found to inhibit the dengue virus protease also inhibited WNV 
protease, albeit with different affinities [10]. Figure 1 displays three of the inhibitors 
found. Compounds 1 and 2 originated from the HTS screen, while compound 3 was 
discovered using the crystal structure of WNV NS2B-NS3pro with bound tetrapeptide [5] 
in an in silico screening approach [11]. 1 and 2 showed inhibition constants in the low 
micromolar range, but no related compounds could be found with inhibition constants 
below 1 µM [10].  
Results of two other published HTS efforts confirmed that discovery of high-affinity 
inhibitors for WNV NS2B-NS3pro is non-trivial. In one study, competitive inhibitors 
with an inhibition constant of about 3 µM were found and their binding to WNV NS2B-
NS3pro modelled [12]. In another, non-competitive inhibitors with IC50 values of about 
0.1 µM were found, but these were prone to hydrolysis with deactivation half-lives of 1-2 
h. The latter are thought to bind to NS3pro, displacing the C-terminal β-hairpin of NS2B 
from NS3pro [13]. HTS campaigns against the WNV replicon, where the target protein is 
unknown, equally failed to discover non-peptidic inhibitors with inhibitory activities 
much below 1 µM [14,15], with EC50 = 0.85 µM reported for the most active compound 
[16].  
In order to improve our understanding of the action of compounds 1 – 3 against WNV 
NS2B-NS3pro, structural information about their binding modes must be obtained. 
Despite many efforts, however, no crystal structure of the protease could be determined 
in complex with 1 – 3 or any other low molecular weight inhibitor. In view of the 
capability of NS2B to undergo a large structural change between proteolytically 
deactivated and fully active states as observed in crystal structures [4,5], competitive 
inhibition could quite conceivably be achieved by binding to an allosteric site rather than 
to the active site. We therefore turned to solution NMR spectroscopy to identify the 
binding sites of 1 – 3 to WNV NS2B-NS3pro. 
We have previously described a model of 3 bound to WNV NS2B-NS3pro, obtained 
by automatic computational docking, which is in agreement with the intermolecular 
NOEs reported here [11]. Ref. [11] also presented the dissociation constant of 3 measured 
by NMR and, as additional proof for binding of 3 to the substrate binding site, 
 6 
demonstrated changes in cross-peak positions for residues lining the substrate binding 
site, without discussing the complete resonance assignment.  
In the following we report protocols for the expression of isotope labelled WNV 
NS2B-NS3pro in high yields in E. coli in vivo and by cell-free synthesis, the first 
virtually complete assignments of the 15N-HSQC spectrum, structure analysis of WNV 
NS2B-NS3pro with bound inhibitor, and identification of intermolecular NOEs between 
the inhibitors and the protease. 
 
 
Results 
 
Sample preparation  
 
The original construct of NS2B-NS3pro (construct 1, Figure 2) was toxic to E. coli, 
leading to cell lysis on plates prepared with rich media as well as in large-scale 
preparations. Improved protein yields were obtained by a modified protocol, where E. 
coli colonies grown on M9 media plates were selected prior to large-scale expression. In 
this way, 9.3 mg of purified uniformly 15N/13C-labelled protein were obtained per liter of 
a 15N/13C-labelled rich medium (induction by IPTG), while an autoinduction protocol [17] 
yielded as much as 59 mg of purified 15N-labelled protein per litre of cell culture 
(Materials and Methods).  
Construct 1 equally produced hardly any protein in our cell-free protein synthesis 
system [18,19]. This problem was overcome by construct 2 which starts with the first six 
codons from T7 gene 10 which expresses well in cell-free systems. A clone in a high-
copy number T7 plasmid [20] facilitated the preparation of large quantities of DNA 
required for the cell-free synthesis. Typical yields were close to 1 mg of purified protein 
per ml of cell-free reaction mixture. Although acceptable 15N-HSQC spectra could be 
recorded without purification of the protein [21,22], complex formation with the 
inhibitors required purified protein as compounds 1 and 2 also bound to components of 
the cell-free mixture. 
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The NS2B-NS3pro construct 1 in Figure 2 was susceptible to gradual self-cleavage 
by the protease at two sites, following the first glycine in the linker after Lys96NS2B and 
Lys15NS3 (Figure 2) [5,23], resulting in release of the intermittent peptide from the 
protein. As variable extents of cleavage led to sample heterogeneity, later work employed 
the mutant Lys96NS2B->Ala (construct 3) which prevented cleavage at either site [24]. 
The K96A mutant turned out to be also much less toxic to E. coli, producing high yields 
even when overexpression was induced by IPTG. The K96A mutant retained full 
proteolytic activity in the assay used [10] to measure the inhibition constant of different 
ligands (data not shown).  
 
Inhibitor binding monitored by NMR spectroscopy 
 
In the absence of inhibitors, the assignment of the NMR resonances of WNV NS2B-
NS3pro was difficult, as many signals were broadened beyond detection and the spectral 
resolution was poor (Figure 3a). Over 100 different compounds that had been suggested 
by high-throughput docking calculations with a large library of molecules [11] or 
appeared as hits in the in vitro high-throughput screens, were tested for binding to WNV 
NS2B-NS3pro by NMR spectroscopy using 15N-labelled protein. 1D 1H NMR spectra 
were used to assess any line broadening experienced by the low-molecular weight 
compounds and 15N-HSQC spectra were recorded to detect responses in the protein. Most 
of the compounds showed broad lines in the presence of protein without noticeably 
changing the 15N-HSQC spectrum. This situation was interpreted as non-specific binding. 
Other compounds were barely soluble in water. Compounds 1 and 2, however, improved 
the 15N-HSQC spectra of the protein dramatically in a similar manner as compound 3. 
Besides improved spectral dispersion, the 15N-HSQC spectra of the complexes with 2 and 
3 (Figure S1) showed marked similarities, indicating that both compounds stabilize the 
same structure of the enzyme.  
Compound 1 originated from the in vitro screen [10]. It was the first found to improve 
the NMR spectrum of WNV NS2B-NS3pro in a manner very similar to the inhibitor 
benzoyl-norleucine-lysine-arginine-arginine-aldehyde (Bz-nKRR-H) [25] which has been 
used for crystallization [5].  Hence, the first resonance assignments of the protease by 3D 
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NMR spectroscopy were performed using the complex with 1. Compound 2 was 
designed to improve the solubility of 1 and lift its two-fold symmetry in order to facilitate 
the assignment of intermolecular NOEs. 2 bound to WNV NS2B-NS3pro with similar 
affinity as 1 (IC50 of 11 versus 25 µM) [10]. Compound 3 inhibited WNV NS2B-NS3 by 
35% when tested at 25 µM and had a Kd value of about 40 µM as measured by NMR [11]. 
Similar to 3 [11], as 1 or 2 were added to the enzyme some of the 15N-HSQC peaks 
shifted, indicative of chemical shift averaging by chemical exchange on a time scale of 
tens of milliseconds, while others appeared at new positions, as expected for slow 
exchange in the limit of large chemical shift differences between the free and complexed 
protein (Figure S2). The 15N-HSQC spectra did not change significantly when the 
inhibitors were used in excess.  
 
Resonance assignments 
 
The quality of the 15N-HSQC spectra obtained in the presence of 1, 2 or 3 was 
sufficient for sequential resonance assignments using conventional triple-resonance 3D 
NMR experiments. NMR spectra of NS2B-NS3pro and NS2B-NS3pro(K96A) were 
closely similar, as expected for a point mutation in a mobile segment of the polypeptide 
chain. Increased mobility of the segment surrounding residue 96 in NS2B had been 
suggested by the absence of electron density for the linker peptide between NS2B and 
NS3 following Asp90 in the crystal structure with BPTI [4] and was confirmed by narrow 
NMR line shapes.  
The resonances of the complex with 1 were assigned using NS2B-NS3pro while the 
3D NMR experiments of the complexes with 2 and 3 employed the WNV NS2B-
NS3pro(K96A) mutant. The resonance assignments of the complexes with 1 and 3 were 
supported by combinatorial 15N-labelling (Figure S3). The assignments of the backbone 
amide cross-peaks are shown in Figure S4. Resonance assignments were obtained for the 
backbone amides of the segments comprising residues 50-96 of NS2B and 17-187 of 
NS3pro, with the exception of prolines and a few residues with very broad amide peaks. 
The resonances of the peptide connecting NS2B and NS3pro appeared at chemical shifts 
characteristic of random coil conformation and were not assigned. 
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Conformation of WNV NS2B-NS3pro induced by inhibitors 
 
NOEs between NS2B and NS3pro observed for the complex with 2 showed that 
NS2B docks to NS3pro as in the crystal structures with peptidic inhibitors (Table 1) [4-6]. 
Furthermore, the similarity of the backbone-amide chemical shifts of the complexes with 
1, 2 and 3 (e.g. Figure S1) indicated that NS2B assumes the same conformation in the 
presence of any of the three compounds. The crystal structures of NS2B-NS3pro in 
complex with peptide inhibitors or BPTI [4-6] are thus suitable starting points for 
modelling the complexes with the low-molecular weight inhibitors of the present study.  
 
Inhibitor binding sites 
 
As the NMR spectra of the protease complexes with 1 and 2 were very similar, both 
compounds must bind in the same way. Therefore, we only studied the binding of the 
non-symmetric and more soluble compound 2 by intermolecular NOEs. In the 1:1 
complex with the protease, the proton resonances of the phthalazine ring of 2 were too 
broad to be observable. (1 behaved in the same way.) Therefore, we used 2 in about 3-
fold excess over the protease in order to measure intermolecular NOEs. The maximal 
solubility of 2 in water was about 3 mM, but aggregation occurred already at much lower 
concentrations. Thus, even at 0.3 mM concentration, the NMR line widths of 2 were 
broader than expected for a monomeric compound (Figure S5). Furthermore, negative 
intramolecular NOEs were observed for a sample at 0.7 mM concentration, indicating an 
effective molecular weight >500 Da. The possibility of self-association made it harder to 
interpret the intermolecular NOEs observed between the protease and 2. Consequently, 
we used the NOE data with 3 to support the assignment of intermolecular NOEs with 2. 
Figure 4 shows intermolecular NOEs observed between WNV NS2B-NS3pro(K96A) 
and 3. Although most NOEs could readily be assigned, the difficulty to obtain complete 
side-chain resonance assignments for the protein prompted us to seek additional 
verification that 3 binds to the active site of the protease.  
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In the first experiment, we compared the 15N-HSQC spectra of WNV NS2B-
NS3pro(K96A) in the presence of 3 and in the presence of the Bz-nKKR-H inhibitor used 
in one of the crystal structure determinations [5]. As expected for closely related binding 
sites, the spectra were very similar except for chemical shift changes for some of the 
residues lining the active site (Figure S6). 
In another experiment, selectively 15N-Gly labelled samples of WNV NS2B-NS3pro 
were prepared of the wild-type protein and of the Gly151Ala mutant. Gly151 is located in 
close proximity of the active-site histidine residue and mutation to alanine should not 
only interfere with enzyme activity, but also with inhibitors that bind to the substrate 
binding site. Indeed, the G151A mutant was inactive in the enzymatic assay [26] and 
unable to bind 3 (Figure S7). 
Having established that compound 3 binds to the substrate binding site, we used the 
INPHARMA strategy [27] to verify binding to the substrate binding site also for 
compound 2. Indeed, a NOESY spectrum of 2 and 3 in the presence of a small quantity of 
protease revealed an intermolecular cross-peak between the methyl group of 3 and the 
phthalazine ring of 2 as expected for an overlapping binding site (Figure 5).  
Table 2 compiles the intermolecular NOEs observed with 2 and 3. The NOEs with 
Ile155 were most readily assigned due to their characteristic chemical shifts, while other 
NOEs were assigned using the assumption that the protease fold was that observed in the 
crystal structures with peptide inhibitors. The fact that all intermolecular NOEs observed 
with the aromatic ring proton of 3 were also observed with the methyl group probably 
was, in most cases, a consequence of spin-diffusion. Relaxation during the half-filter 
delays and the 2-fold symmetry of 3 further impeded accurate distance measurements. 
The data show that both inhibitors are in proximity of Thr132 and Ile155. There are, 
however, also significant differences between the binding modes of the two compounds. 
For example, 3 contacts the side-chain of His51 in the active site, whereas no equivalent 
interaction could be found for 2. No intermolecular NOE with NS2B could be observed 
due to the difficulty to observe proton resonances of amino and guanidinium groups.  
 
Model building 
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Docking of compound 2 was performed automatically by DAIM/SEED/FFLD [28-32] 
using the PDB coordinate set 2FP7 [5] as described earlier for 3 [11]. For each compound 
a total of 50 poses were kept upon clustering. The pose which best satisfied the 
intermolecular NOEs (Table 2) was selected as the final model. Not all cross-peaks 
observed for 2 (Table 2) could be explained as direct NOEs with the protease. This could 
be due to spin-diffusion during the mixing time of the NOESY experiment, movements 
of the ligand in the binding pocket or differences in side chain orientations between the 
crystal and solution structure. (For example, the side-chain of Ile155 is differently 
oriented in the structure with BPTI (χ1 = -66o) [4] than in the structure used for Figure 6 
(χ1 = -180o) [5] and the intermolecular NOEs observed with Ile155 are in much better 
agreement with χ1 = -180o than χ1 = -66o.) In the case of aggregation-prone compound 2, 
binding of more than a single molecule may have confounded the interpretation of 
intermolecular NOEs. Nonetheless, the model of Figure 6a satisfies most NOEs. It places 
the positively charged cyclic amidine group near the negatively charged side chain of 
Asp129 which interacts with the positively charged side chain of the P1 residues of Bz-
nKKR-H [5] and BPTI [4]. The primary amino group of 2 points towards the C-terminal 
β-hairpin of NS2B which carries three aspartate residues in a row in positions 80-82. 
Although 2 belongs to a different class of compounds than 3, the binding modes of both 
compounds are not dissimilar (Figure 6).  
 
 
Discussion 
 
Competitive inhibition is usually accepted as strong indication that the binding sites 
of two inhibitors are at least partially overlapping. In the case of the WNV NS2B-NS3 
protease, the C-terminal β-hairpin of NS2B is essential for catalytic activity, but has been 
found far away from the substrate binding site in the absence of inhibitor [4]. In addition, 
the substrate binding site changes significantly between the structures with and without 
inhibitor, so that competitive inhibition could conceivably be achieved by binding to a 
site that prevents NS2B from correct association with the substrate binding site. In this 
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situation, NMR spectroscopy provides an important tool for the identification of the 
inhibitor binding site. 
No sequence-specific NMR resonance assignments have been reported to date of the 
WNV NS2B-NS3 protease. The poor quality of the NMR spectrum of WNV NS2B-
NS3pro in the absence of inhibitors is reminiscent of the situation in the homologous 
NS2B-NS3pro construct from dengue virus type 2, where selectively 15N/13C-labelled 
samples show a great variation in NMR line-width, prohibiting conventional assignment 
strategies by multi-dimensional NMR spectroscopy [33]. The dramatic improvement in 
spectral quality observed upon formation of complexes with our inhibitors is readily 
explained by a shift of conformational exchange equilibria towards a single conformer. 
NOEs between NS2B and NS3 indicate that this conformer is related to the conformation 
observed in the crystal structures of the complex with peptidic inhibitors [4-6], where the 
C-terminal β-hairpin of NS2B is positioned near the substrate binding site rather than far 
away as in the crystal structure in the absence of inhibitor [4]. We were able to obtain this 
result without optimised engineering of the NS2B part that had been required to obtain an 
acceptable NMR spectrum of the closely related dengue virus NS2B-NS3 protease [34]. 
The NMR data clearly show that the small synthetic inhibitors 1 - 3 bind to the 
substrate binding site of WNV NS2B-NS3pro. Competitive inhibition with established 
peptide inhibitors is thus effected by direct competition rather than by indirect 
competition via an allosteric inactivation mechanism. Considering the apparent ease with 
which the C-terminal β-hairpin of NS2B is brought into the vicinity of the active site, our 
results indicate that the crystal structures of the protease-peptide complexes are valid 
starting points for the search of low molecular weight inhibitors. Indeed, compound 3 is 
the first inhibitor of WNV NS2B-NS3pro that has been discovered by a computer search 
using the crystal structure with a tetrapeptide inhibitor as a template [5, 11]. An important 
implication is that the only available crystal structure of the corresponding dengue virus 
protease [5] is not a suitable starting point, because it positions the C-terminal β-hairpin 
of NS2B far from the substrate binding site. 
Although compounds 1 – 3 induce a more uniform structure of WNV NS2B-NS3pro, 
they are not able to suppress all conformational exchange. For example, we could not 
assign the backbone amides of Thr132, Gly133, and Gly151 even in the presence of 1, 2, 
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or 3, and the backbone resonances of neighboring residues were broad. All three residues 
line the substrate binding-pocket. In order to find improved inhibitors, it is thus relevant 
to explore the conformational space of the protease in a molecular dynamics (MD) 
simulation rather than relying exclusively on the structures observed in the solid state. 
Intriguingly, the Thr132-Gly133 peptide bond was found to flip spontaneously in the 
course of a recently performed 50 ns MD simulation [35]. A flip of this peptide bond also 
presents the main difference in backbone conformation of the substrate binding site 
between the crystal structures 2IJO and 2FP7 [4]. 
The Gly4-Ser-Gly4 linker connecting NS2B and NS3pro appeared to be highly 
flexible in solution as the corresponding signals appeared to be strongly overlapped in an 
intense cluster of peaks at a chemical shift characteristic of a random coil peptide chain. 
Structural variability of these residues has initially been suggested by the absence of 
electron density for the linker residues and the C-terminal residues of NS2B following 
Asn89 in the WNV NS2B-NS3pro(K96A) mutant in complex with BPTI [4]. Also the 
recent structure of the protease in complex with a tripeptide inhibitor misses electron 
density for, respectively, three or all of the residues of the Gly4-Ser-Gly4 linker in the two 
conformers reported [6]. The high mobility observed by NMR for the peptide linker in 
solution provides a firm explanation for the finding that the covalent linkage between 
NS2B and NS3 does not restrain the function of the protease [2,9]. 
In conclusion, compounds 1 and 2 bind to the substrate binding site of the WNV 
NS2B-NS3 protease. Their binding site overlaps with that of compound 3 (Figure 6). 
Remarkably, even these small, non-peptide inhibitors can stabilize the conformation of 
NS2B observed in crystal structures with peptides. This result provides crucial validation 
for the use of computational approaches that start from the crystal structures obtained 
with peptide inhibitors [11]. We are confident that further computations that take into 
account the conformations sampled by MD simulations will lead to non-peptidic lead 
compounds with submicromolar affinity. 
 
 
 
Materials and Methods 
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Materials 
 
Compounds 1 and 2 were synthesized in-house. Compound 3 was obtained from 
Maybridge, NJ, USA (Cat# S01870SC). Spectra 9 (13C, 15N) media was obtained from 
Spectra Stable Isotopes. 15NH4Cl, 
13C/15N-Silantes (OD2) media, 15N-glycine, 13C/15N-
tyrosine, and 13C/15N-phenylalanine were purchased from Cambridge Isotope 
Laboratories. E. coli strains Rosetta::λDE3/pRARE and BL21 Star::λDE3 were obtained 
from Novagen and Invitrogen, respectively. Synthetic oligonucleotides were purchased 
from GeneWorks. Sequences of oligonucleotides used are listed in the Supporting 
Information. Vent DNA polymerase and Phusion DNA polymerase were obtained from 
New England BioLabs. Qiaquick PCR purification and Qiaquick gel extraction kits were 
purchased from Qiagen. 
 
Preparation of uniformly 
15
N-labelled WNV NS2B-NS3pro  
 
The E. coli strain Rosetta::λDE3/pRARE was transformed with the plasmid pET15b-
WNV CF40GlyNS3pro187 (construct 1 of Figure 2) [5] on LB plates containing 100 
µg/ml ampicillin and 50 µg/ml chloramphenicol. A single transformant colony (about 108 
cells) was diluted with LB media to about 107 cells in 1 ml LB and 100 µl batches of the 
diluted cells were plated on fifteen M9 minimal media plates, containing 5 mM glucose 
and 0.2%(w/v) glycerol, 100 µg/ml ampicillin, and 50 µg/ml chloramphenicol. Following 
growth for two days at 37 ˚C, the colonies were collected and resuspended in small 
volumes of M9 media. About 100 OD595 units of cells were used to inoculate 500 ml of 
15N-autoinduction media containing 0.5 g/l 15NH4Cl, 100 µg/ml ampicillin, and 50 µg/ml 
chloramphenicol [17]. 4 conical 2-liter flasks, each containing 500 ml of 15N-
autoinduction cultures, were shaken at room temperature at 200 rpm for 2 days up to an 
OD595 value of about 5, yielding about 16.6 g of cells. The cells were suspended in 80 ml 
of buffer A (50 mM HEPES, pH 7.5, 300 mM NaCl, 5% glycerol, 20 mM imidazole) and 
lysed by a French press (12000 psi, 2 passes). After centrifuging the lysate at 18000 rpm 
for 1 h, the supernatant was filtered through a 0.45 µm Millipore filter. The filtrate was 
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directly loaded on a 5 ml Ni-NTA column (Pharmacia). The bound 15N-WNV NS2B-
NS3pro was eluted with an imidazole gradient from 20 mM to 500 mM in buffer A. The 
overall yield of purified protein was 118 mg per 2 litres of culture. The protein 
concentration was determined spectrophotometrically at 280 nm, using a calculated ε280 
value of 55760 [36] and the purity checked by SDS-PAGE.  
For subsequent testing of different compounds by 15N-HSQC spectra in 3 mm NMR 
tubes, the protein was subdivided into over 100 batches of 200 µl each, containing 7 
mg/ml protein in NMR buffer (20 mM HEPES-KOH, pH 6.98, 90% H2O/10% D2O, 1 
mM TCEP or 2 mM DTT). A sample was prepared for each individual compound by 
injecting 3 µl of 100 mM solutions of compound in d6-DMSO into 200 µl of aqueous 
protein solution in a 3 mm NMR tube. 
 
Preparation of uniformly 
13
C/
15
N-labelled WNV NS2B-NS3pro 
 
13C/15N-labelled WNV NS2B-NS3pro was prepared using the same protocol as for 
15N-labelled WNV NS2B-NS3pro, except that 2x 500 ml of 13C/15N-Silantes media (OD2) 
were used which were supplemented with 100 µg/ml ampicillin and 33 µg/ml 
chloramphenicol. The cells were grown at 37 ˚C and 200 rpm for 6 h before induction 
with 0.6 mM IPTG at OD595 = 0.95. The induced cells were grown at room temperature 
overnight to OD595 = 1.1, yielding about 1.8 g of cells which were suspended in 20 ml 
buffer A for purification as described above. The final yield of 13C/15N-labelled protease 
was 9.3 mg in NMR buffer. The sample used for 3D NMR experiments was 0.4 mM in 
protein in a 5 mm NMR tube.  
 
Preparation of uniformly 
13
C/
15
N-labelled WNV NS2B-NS3pro(K96A) 
 
A 13C/15N-labelled sample of the K96A mutant of WNV NS2B-NS3pro (construct 3, 
Figure 2) was prepared using the same protocol as for 13C/15N-labelled WNV NS2B-
NS3pro, except that 2x500 ml of 13C/15N-Spectra 9 media were used which were 
supplemented with 100 µg/ml ampicillin and 50 µg/ml chloramphenicol. The cells were 
grown at 37 ˚C and 200 rpm for 3 h before induction with 0.6 mM IPTG at OD595 = 1. 
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The induced cells were grown at room temperature overnight to OD595 = 1.9, yielding 
about 4.4 g of cells which were suspended in 50 ml buffer A for purification on a 5 ml 
Ni-NTA column as described above. Following elution from the column, the protein was 
dialyzed against 1 l of 50 mM Tris-HCl (pH 7.6). The dialysate was loaded on a 7.4 ml 
DEAE-Toyopearl 650M column (2.5 x 1.5 cm) and the bound protease eluted by a NaCl 
gradient from 0 mM to 1 M in a buffer of 50 mM Tris-HCl (pH 7.6) and 1 mM DTT. The 
final yield of 13C/15N-labelled protease was 48.4 mg in NMR buffer. NMR samples were 
0.9 mM in protein.  
 
Cell-free synthesis of WNV NS2B-NS3pro 
 
Construct 2 (Figure 2) was designed for optimum expression yields in a cell-free 
system. Primers 1307 and 1308 (Table S1) were used to amplify the protease gene by 
PCR from the template plasmid pET15b-WNV CF40glyNS3pro187 using Phusion DNA 
polymerase.  Following digestion by NdeI and EcoRI, the PCR fragment was transferred 
into the corresponding site of the pRSET-5b vector [20]. The resulting vector (pRSET-
WNV MASMTGH6-CF40glyNS3pro187) was used for cell-free protein synthesis using a 
cell extract from E. coli. 
S30 cell extracts were prepared from the E. coli strains Rosetta::λDE3/pRARE and 
BL21 Star::λDE3 as described [18,19,37], including concentration with polyethylene 
glycol 8000 [38] and heat treatment of the concentrated extracts at 42 ˚C [39].  
Cell-free protein synthesis was performed for 6-7 h either using an autoinduction 
system with plasmid pKO1166 for in situ production of T7 RNA polymerase [40] or 
using a standard protocol with purified T7 RNA polymerase at 37 ˚C or 30 ˚C [19,22]. 
The reactions were performed with 16 µg/ml target plasmid. Site-directed mutants were 
produced from 5-10 µg/ml PCR-amplified DNA templates. Following cell-free synthesis, 
the reaction mixtures were clarified by centrifugation (30000 × g, 1 h) at 4 ˚C.  
 
Cell-free synthesis of combinatorially 
15
N-labelled WNV NS2B-NS3pro 
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Five sets of 15N-combinatorially labelled samples [41,42] of construct 2 (Figure 2) 
were produced by cell-free protein synthesis. The synthesis was performed using 1 ml 
reaction mixtures for sets 1-4 and 2 ml for set 5. Set 5 was the only reaction containing 
15N-glutamate. This set was prepared using 100 mM potassium succinate in the reaction 
mixture instead of the usual 208 mM potassium glutamate buffer. Cell-free protein 
synthesis was performed at 37 ˚C for 6 h. Following centrifugation, the supernatants were 
diluted with 5-10 ml of buffer A and the proteins purified by a 1 ml Ni-NTA column 
(Pharmacia) using a 20-500 mM imidazole gradient in buffer A.  The buffer of the 
samples was exchanged to 20 mM HEPES-KOH (pH 7.0) and 1 mM TCEP using 
Millipore Ultra-4 centrifugal filters (MWCO 10,000), followed by concentration to a 
final volume of about 0.2 ml. D2O was added to a final concentration of 10% (v/v) prior 
to NMR measurements, resulting in a protein concentration of about 50 µM.  
 
Cell-free synthesis of 
15
N-Gly labelled wild-type and mutant WNV NS2B-NS3pro 
 
Wild-type and mutant (Gly151Ala) samples of selectively 15N-Gly labelled WNV 
NS2B-NS3pro (construct 2) were produced cell-free synthesis from cyclized PCR 
templates [33] using primers 1314, 1315 and 1131-1134 (Table S1). The synthesis was 
performed in 1 ml reaction mixtures, using the same conditions and purification protocol 
as for the combinatorially labelled samples.  
 
NMR measurements 
 
All NMR spectra were recorded at 25 oC using Bruker 800 and 600 MHz Avance 
NMR spectrometers equipped with TCI cryoprobes. Samples of complexes contained 
about 3-fold excess of inhibitor in order to facilitate the observation of intermolecular 
NOEs. 3D spectra recorded included HNCA, HN(CO)CA, CC(CO)NH, (H)CCH-
TOCSY, and NOESY-15N-HSQC (mixing time 60 ms). NOESY spectra with 
13C(ω2)/
15N(ω2)-half-filters (mixing time 120 ms) were used to suppress intramolecular 
NOEs of the protease and observe intermolecular NOEs. For unambiguous identification 
of intra-ligand NOEs, the experiment was also recorded with a 13C-BIRD sequence in the 
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middle of the mixing time which suppressed any NOE from 13C-bound protons of the 
protein. A 3D 13C-HMQC-NOESY spectrum with 13C/15N(ω2)-half-filter (mixing time 
150 ms) facilitated the assignment of the intermolecular NOEs by comparison with the 
(H)CCH-TOCSY spectrum. The chemical shifts have been deposited in the 
BioMagResBank (accession number 11053). 
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Table 1. NOEs observed between NS2B and NS3pro in the presence of 2 or 3 
  
NS2B NS3 distance/Å1 
Trp53 HN Thr27 Hα 3.7 
Ala58 HN Val22 HN 3.1 
Asp59 Hα Val22 H
N 3.6 
Ser72 Hα Gly114 H
N 2.8 
Arg74 Hα Val115 H
N 2.6 
Val77 HN Lys117 HN 3.3 
Gly83 HN Lys73 Hα 2.8 
1Distance in the crystal structure with tetra-peptide inhibitor (2FP7) [5] 
 
 
Table 2. Intermolecular NOEs between WNV NS2B-NS3pro(K96A) and the inhibitors 2 
and 3 
 
Protons of WNV NS3pro  Compound 2a Compound 3 
His51 Hδ2  H1 and CH3 
Tyr130 Hδ H6/H6’  
Thr132 Cϒ2H3 H6/H6’ H1 and CH3 
Thr132 Hα  H1 and CH3 
Thr134 Cϒ2H3 H6/H6’  
Tyr150 Hδ H6/H6’  
Asn152 CβH2 H6/H6’  
Gly153 HN H1  
Val154 CϒH3 H1, H2, H5/H5’ H1 and CH3 
Ile155 Cδ1H3 H1, H2, H3, H4 H1 and CH3 
Tyr161 Hδ  H1 and CH3 
a NOEs identified in Figure 6 are underlined. 
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Figure captions 
 
Figure 1. Synthetic inhibitors 1-3 of WNV NS2B-NS3pro studied in the present work. 
Individual atoms are numbered as reference for NMR resonance assignments. 
 
Figure 2. Amino-acid sequence of the WNV NS2B-NS3pro constructs used. In addition 
to the sequence shown, constructs contained the N-terminal sequences 
MGSSHHHHHHSSGLVPRGSHM (construct 1) or MASMTGHHHHHH (construct 2, 
Materials and Methods). A third construct (construct 3) contained the mutation Lys96NS2B 
-> Ala with N-terminal MASMTGHHHHHH peptide (WNV NS2B-NS3pro(K96A)). All 
constructs ended at residue 187 of NS3. Vertical lines identify two autocatalyic cleavage 
sites [24]. The K96A mutation prevents self-cleavage at either site. Residues without 
backbone resonance assignments (disregarding proline) are highlighted in yellow.  
 
Figure 3. 15N-HSQC spectra of WNV NS2B-NS3pro(K96A) in the absence and presence 
of the inhibitor 2 at 25 oC. The samples contained 0.9 mM protein in 90% H2O/10% D2O 
containing 20 mM HEPES buffer (pH 7.0) and 2 mM DTT. The complex with 2 was 
prepared by adding 15 µl of 100 mM solutions of inhibitor in d6-DMSO to the protein 
solution. The spectra were recorded at a 1H NMR frequency of 800 MHz. (a) 15N-HSQC 
spectrum in the absence of inhibitor. (b) 15N-HSQC spectrum in the presence of 
compound 2 (3 mM). 
 
Figure 4. 2D NOESY spectrum with 13C(ω2)/
15N(ω2)-half-filter of WNV NS2B-
NS3pro(K96A) in complex with 3. Parameters: 0.9 mM protein and 2 mM 3 in 90% 
H2O/10% D2O containing 20 mM Tris-HCl buffer (pH 7.2) and 2 mM DTT, 25 
oC,   
mixing time 120 ms, t1max = 34 ms, t2max = 86 ms, 800 MHz 
1H NMR frequency. 
Intermolecular NOEs with the aromatic ring protons of 3 are marked with their 
assignments. Several of the NOEs are also observed with the methyl groups of 3 at 2.3 
ppm. 
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Figure 5. 2D NOESY spectrum 0.6 mM 2 and 0.5 mM 3 in the presence of 0.03 mM 
WNV NS2B-NS3pro(K96A) in D2O at 25 
oC. Under these conditions, the signals of 2 
were sufficiently narrow to be observable (Figure S4c). Other parameters: mixing time 
150 ms, t1max = 35 ms, t2max = 71 ms. The cross-peak between 3 H3 and 2 H6 or H6’ is 
assigned as well as the intramolecular NOE between 3 H3 and H1.  
 
Figure 6. Stereo views of models of 2 and 3 bound to WNV NS2B-NS3pro. The protein 
structure is that by Erbel et al. [5], with NS2B drawn as a grey ribbon. Heavy atom 
representations of 2 and 3 are drawn in black. The side chains of residues for which 
intermolecular NOEs are reported in Table 2 are shown in a stick representation. (a) 
Complex with 2. Selected intermolecular NOEs (Table 2) are highlighted with magenta 
lines. (b) Complex with 3 reported in ref. [11].  
 
 
